COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Original-Research: Marley Spoon Group SE (von NuWays AG): BUY
Latest research report by NuWays AG recommends buying Marley Spoon Group SE, citing operational progress and potential benefits from the delisting of Marley Spoon SE from the ASX. Q4 sales in line with expectations, despite macroeconomic challenges -
-
COMMUNIQUÉ DE PRESSE
Original-Research: EV Digital Invest AG (von NuWays AG): HOLD
EV Digital Invest AG analyzed by NuWays AG is recommended as HOLD with a reduced price target of €4.80 based on DCF. Analyst sees potential for recovery in the real-estate sector and cross-selling opportunities with wevest. ECSP license enables new products and offerings in the renewable energy space. Management board changes. Full analysis available at http://www.more-ir.de/d/28787.pdf or www.nuways-ag.com/research -
COMMUNIQUÉ DE PRESSE
Original-Research: 123fahrschule SE (von NuWays AG): BUY
123fahrschule SE is expected to report a 21% increase in total sales for FY '23, driven by growth in the Private Customer and Professional Drivers Education segments. Despite a neutral EBITDA at 9M '23, the company is positioned to improve profitability in FY '24e, with expectations of further growth and positive EBITDA by FY '25e. The full analysis is available for download at http://www.more-ir.de/d/28783.pdf -
-
COMMUNIQUÉ DE PRESSE
Abivax annonce une mise à jour de son programme de développement clinique de phase 2b avec obefazimod dans la maladie de Crohn modérément à sévèrement active
Abivax annonce une mise à jour de son programme de développement clinique de phase 2b avec obefazimod dans la maladie de Crohn modérément à sévèrement active. L'initiation de l’inclusion des patients est prévue pour le troisième trimestre 2024, les données d'induction à 12 semaines sont attendues au deuxième semestre 2026 -
COMMUNIQUÉ DE PRESSE
Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
Abivax updates obefazimod Phase 2b clinical program in Crohn’s disease following FDA feedback. Trial design modification to align with FDA recommendations. Patient enrollment to start in Q3 2024 -
-
